Reuters -- Alexion Pharmaceuticals Inc posted better-than-expected quarterly results, helped by the addition of new patients receiving its genetic disorder drug Soliris in the United States and Europe, and raised its full-year outlook.
Reuters -- Alexion Pharmaceuticals Inc posted better-than-expected quarterly results, helped by the addition of new patients receiving its genetic disorder drug Soliris in the United States and Europe, and raised its full-year outlook.
